Corning Life Sciences

Listen to this article on the DDW Podcast: An expert’s view by John Yoshi Shyu, Ph.D. Corning Life Sciences. Most vaccines are manufactured using technology devised fifty or more years ago, in manufacturing plants that are sometimes even older. The vaccine production process is continually refreshed by new tools and technologies, and that fast-paced innovation gives […]

Corning Life Sciences will be hosting a virtual 3D Cell Culture Summit, June 16-17, that will bring together industry leaders and innovators to share ideas and information, and to discuss the future of 3D applications including spheroid, organoid and tissue models 3D workflow optimisation, trends, and innovation. Some of the topics covered include: Human Pluripotent […]

The HepGo Assay-ready 3D Liver Spheroid Kit leverages Corning Life Science’s 3D cell culture technology in liver biology and ADME/Tox. Corning has developed an all-in-one solution for the development of 3D liver models that has been designed to better recapitulate in vivo behaviour. The kit is said to deliver a more physiologically relevant model over […]

By John Yoshi Shyu, Ph.D. Corning Life Sciences. Gene therapy – the addition, deletion, or modification of genes in living organisms – has been around, at least in concept, since the 1980s. Gene modification or editing incorporates two main strategies: insertion of novel genetic constructs into existing genes, and gene inactivation or silencing.1 As of […]

Dr. Kacey Ronaldson-Bouchard (pictured) explains why adapting cell-based assays from suspension cells to 2D culture, 3D culture, and beyond to ‘patient in a dish’ systems is not an exercise undertaken lightly. However, the effort pays off on many levels.  Our incomplete understanding of human biology and the limited potential for human experimentation underscore the need for […]